14 months after reporting disappointing Phase II results in acute myeloid leukemia, Karyopharm Therapeutics Inc. has returned with some promising and "very exciting" top-line data from the Phase IIb STORM study of selinexor in patients with multiple myeloma that is resistant to multiple lines of other therapies.
Karyopharm intends to submit a US NDA for selinexor in the second half of 2018, the company told an analysts' meeting on May 1, the day after the company's share price rose by 27% in
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?